Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Rhea-AI Summary
mdxhealth (NASDAQ: MDXH) presented late-breaking data from Oxford’s GPS-ProMPT study at EAU 2026 showing the Genomic Prostate Score (GPS mdx) predicts adverse outcomes across active surveillance, surgery, and radiotherapy.
The 409-patient cohort with a median follow-up of at least six years showed 6-year freedom-from-failure of 92% in active surveillance and up to 100% for surgery or radiotherapy, indicating GPS mdx can identify biologically indolent cancers among clinically higher-risk patients.
Positive
- 409-patient cohort evaluated
- Median ≥6-year follow-up reported
- 6-year freedom-from-failure 92% in active surveillance
- 6-year freedom-from-failure up to 100% in surgery/radiotherapy
Negative
- Study cohort limited to 409 patients
- Follow-up described as "at least six years" without exact median
News Market Reaction – MDXH
On the day this news was published, MDXH declined 0.30%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $549K from the company's valuation, bringing the market cap to $183M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While MDXH is up 2.97%, key diagnostics peers show flat to negative moves, including BNR at -5.49% and PRE at -3.63%, suggesting a stock-specific reaction to the GPS data rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings results | Positive | -4.2% | Reported FY 2025 revenue growth and reaffirmed 2026 guidance with margin targets. |
| Feb 12 | Earnings preview | Neutral | -0.6% | Announced timing and access details for Q4 and full‑year 2025 results call. |
| Jan 12 | Prelim results & guidance | Positive | +5.2% | Released preliminary 2025 revenues, strong unit volumes, 2026 guidance, and earnout changes. |
| Jan 06 | GPS trial collaboration | Positive | -3.0% | Initiated GPS testing in UK ProtecT trial to generate randomized clinical evidence. |
| Nov 12 | Q3 earnings & acquisition | Positive | -3.6% | Reported Q3 growth and closed Exosome Diagnostics acquisition to expand test menu. |
Recent history shows multiple instances where positive earnings or clinical news were followed by negative price reactions, indicating a tendency for the stock to sell off on good news, with occasional upside on guidance-heavy updates.
Over the last several months, mdxhealth has reported steady growth, with Q3 and full-year 2025 results showing double‑digit revenue increases and improving adjusted EBITDA. The company also expanded its prostate cancer diagnostics portfolio through the Exosome Diagnostics acquisition and advanced validation work for its GPS test with the University of Oxford, including the GPS‑ProtecT initiative. Today’s ProMPT data further build on prior GPS-focused announcements, adding long‑term outcome evidence across multiple treatment settings to support clinical utility and potential adoption.
Regulatory & Risk Context
An effective F-3/A shelf dated 2026-02-11 registers up to $200,000,000 of ordinary shares and includes a $50,000,000 at-the-market program, providing flexibility for future equity issuance. Shelf risk factors highlight continued losses, an accumulated deficit of $369.5 million, going-concern considerations, a credit facility of up to $100 million, and deferred acquisition obligations of up to $64.5 million that may require substantial cash or share payments.
Market Pulse Summary
This announcement highlights long-term GPS-ProMPT data in 409 prostate cancer patients, with at least six years of follow-up and strong six‑year freedom‑from‑failure rates up to 100% across treatment modalities. It builds on mdxhealth’s earlier Oxford collaborations to reinforce the GPS test’s prognostic value. In parallel, the company maintains an effective $200,000,000 shelf and has disclosed ongoing losses and acquisition-related obligations, making future financing decisions and execution on revenue guidance important metrics to watch.
Key Terms
genomic prostate score medical
active surveillance medical
radical prostatectomy medical
radiotherapy medical
median follow-up medical
treatment de-escalation medical
AI-generated analysis. Not financial advice.
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
IRVINE, California – March 16, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were presented on March 13th at the 41st Annual European Association of Urology (EAU) Congress, in London.
The late-breaking abstract from the GPS-ProMPT study, led by investigators at the University of Oxford, highlighted how the GPS mdx assay identified patients with biologically indolent prostate cancer despite adverse clinical risk factors. The findings demonstrate how GPS mdx insights help personalize treatment decisions by identifying patients who may safely benefit from treatment de-escalation.
The study was presented by Professor Freddie Hamdy, Nuffield Professor of Surgery and Professor of Urology at the University of Oxford, a globally recognized leader in prostate cancer research and one of the field’s most influential clinical investigators
“This presentation represents the first major milestone in our research collaboration with the University of Oxford and is an important step forward as we advance the GPS-ProtecT study together. As we continue to build on the outstanding investigative work led by Professor Freddie Hamdy and his team at Oxford, we expect to generate some of the most meaningful clinical evidence to date for our Genomic Prostate Score test and further strengthen the role of genomic insights in guiding more personalized prostate cancer care,” said Michael K. McGarrity, CEO of mdxhealth.
The GPS-ProMPT study evaluated 409 patients with localized or locally advanced prostate cancer with a median follow-up of at least six years. Patients in the cohort were managed with active surveillance, radical prostatectomy, or radiotherapy, enabling investigators to assess the predictive performance of the GPS mdx test across multiple treatment pathways. The GPS mdx test successfully stratified the risk of treatment failure across treatment cohorts. Six-year freedom-from-failure outcomes were excellent in these discordant groups, including
Professor Hamdy, University of Oxford, commented, “These results demonstrated that genomic insights from the GPS mdx test can identify patients with favorable tumor biology even among clinically higher-risk groups, helping clinicians better tailor treatment strategies and potentially avoid overtreatment.”
About the GPS-ProtecT Study
On January 6, 2026, mdxhealth announced the next major phase of its collaboration with the University of Oxford with the initiation of GPS mdx testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment), designed to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance (AS) cohort, further validating the clinical utility of GPS mdx in predicting prostate cancer progression and long-term treatment outcomes. The UK ProtecT trial is widely regarded as the world’s largest randomized clinical trial of treatment effectiveness in localized prostate cancer. Following more than 1,500 men with localized disease for over two decades, the trial provides unmatched long-term clinical outcome data across AS/AM, Radical Prostatectomy (RP), and Radiotherapy (RT).
About GPS mdx
The GPS mdx test is a 17-gene expression assay that provides personalized genomic insights to help guide treatment decisions for patients with localized prostate cancer. Performed on prostate biopsy tissue, the test evaluates tumor biology to estimate the risk of adverse pathology, high-grade disease, non-ogran confined disease, metastasis within 10 years, prostate cancer death within 10 years and disease progression beyond traditional clinical and pathological factors. These insights help physicians better personalize care, supporting decisions between active surveillance and definitive treatment. The clinical performance and utility of the GPS mdx test have been demonstrated in multiple peer-reviewed studies and the test is recognized in leading clinical guidelines for prostate cancer management.
About mdxhealth
Mdxhealth is a leader in urology-focused precision diagnostics, providing actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: x.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
LifeSci Advisors (IR & PR)
John Fraunces, Managing Director
Tel: +1 917 355 2395
jfraunces@lifesciadvisors.com
Forward-Looking Statement: This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding expected future operating results; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated timing and benefits of our acquisitions, including estimated synergies and other financial impacts. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of our products and services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; changes in payer claims reimbursement practices and MDxHealth estimates regarding collection amounts for tests; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash will be sufficient to fund our future operating expenses and capital expenditure requirements; our ability to remain in compliance with financial covenants made to and make scheduled payments to our creditors; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the Exo mdx and GPS mdx prostate cancer businesses will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS mdx, GPS, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate Intelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of MDxHealth SA and its affiliates. The GPS mdx test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark and all other trademarks and service marks, are the property of their respective owners.
Attachment
FAQ
What did mdxhealth announce about the GPS mdx results at EAU 2026 (MDXH)?
How large was the GPS-ProMPT study presented by mdxhealth (MDXH) at EAU 2026?
What do the 6-year outcomes for GPS mdx mean for active surveillance patients (MDXH)?
Did the GPS mdx test predict outcomes after surgery and radiotherapy in the ProMPT study (MDXH)?
What are the limitations of the GPS-ProMPT data presented by mdxhealth (MDXH)?
